This patent document diclsoes novel compounds and methods of preventing or treating diseases or conditions related to Keapl-Nrf2 interaction activity by use of the novel compounds. As direct inhibitors of Keapl-Nrf2 interaction, the compounds disclosed herein are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential dmg candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, Parkinson's, and inflammatory bowel disease including ulcerative colitis.
这项专利文件披露了一种新颖的化合物和方法,通过使用这些新颖的化合物来预防或治疗与Keapl-Nrf2相互作用活性相关的疾病或状况。作为Keapl-Nrf2相互作用的直接
抑制剂,本文披露的化合物比现有的间接
抑制剂更具特异性,且不受各种不良影响,是潜在的
化学预防和治疗剂的候选人,用于治疗涉及氧化应激和/或炎症的各种疾病或状况,包括但不限于癌症、糖尿病、阿尔茨海默病、帕
金森病和溃疡性结肠炎等。